Source: China – South China Morning PostA Chinese biotech start-up developing a protein-based Covid-19 vaccine has signed an advance purchase agreement to supply up to 414 million doses for global use by next year.Gavi, the Vaccine Alliance, a public-private partnership, announced the deal with Clover Biopharmaceuticals on Wednesday on behalf of the Covax Facility, an initiative that aims to ensure equitable access to Covid-19 vaccines for low and middle-income countries.Should the vaccine be approved by the World Health Organization…Read More